• HOME
  • Call for Abstracts

Call for Abstracts

Call for Abstracts

How to submit abstracts

All submissions will be accepted online.
Please click on the "Abstract Submission" button at the bottom of this page.

When to submit abstracts

There will be no extension of the submission deadline. Please submit your abstracts before the deadline.
※Please note that online acceptance of abstracts will end automatically at noon on Monday, November 25 (JST)

October 1 (Tue), 2024 at noon – November 25 (Mon), 2024 at noon (JST)

Abstract Submission Guidelines

  1. Abstract Restrictions
    Submit ONLY ONE abstract per first author, with the exception of co-presenters.
    *Registration by first author in person is required.
  2. Information to submit
    • Language of presentation: English
    • Presentation format: oral or poster presentation
    • Presentation category: Please check the Category list for details.
    • Names of first author (presenter) and co-authors: No more than 20 presenters
    • Affiliations of first author (presenter) and co-authors: No more than 10 affiliations
    • Abstract title: No more than 100 half - width (1-byte) characters including spaces in English
    • Abstract format
      • - Abstracts must be submitted in English.
      • - Abstracts should be no more than1,600 half-width (1-byte) characters including spaces in English.
      • - The abstract should be divided into succinct sections for "Objective," "Methods," "Results," "Conclusions," and so on. There is no need for line breaks after headings or between lines. It wouldn't be reflected on the book of abstracts, even if you used the tag to add a line break.
      • - Incomplete abstracts (i.e. abstracts with typos, missing letters/words, missing specific numbers, missing "Objective," "Methods," "Results," and "Conclusions" sections, etc.) will not be accepted, so please be especially careful when preparing abstracts for submission.
  3. Eligibility for Abstract Submission
    • The first author must be a doctor or a researcher engaged in clinical neurology, research on neuroscience, or related fields, and should agree to the main outline and activities of JSN
    • The first author himself/herself should register for the meeting and submit an abstract.
      Submission of an abstract by a co-author on behalf of the first author is not permitted.
    • The presenting author must be the first author of the submitted abstract.
  4. Guidelines for ethical considerations
    The submitting author certifies that any work with human or animal subjects reported in this abstract complies with the guiding principles for experimental procedures endorsed by the ethical review board of the country in which the study was done.
    Abstracts must comply with relevant ethical guidelines for human and/or animal research, and authors may be asked to provide additional documentation.

    If the study was conducted in Japan, please follow the guideline below:
    Depending on the nature of the research to be presented, it may be necessary to adhere to ethical guidelines (for clinical research, human genome/genetic analysis research, immunological research, clinical research using human stem cells, etc.) established by the Ministry of Health, Labor and Welfare or other agencies, as well as the ethical rules (including those for animal research, etc.) set forth by presenters' affiliations, and to obtain prior review and approval from their institution's ethical review boards, etc. For further information, please see "Ethical Considerations in Abstracts for the Annual Meeting of the Japanese Society of Neurology"

    *However, it is not necessarily required to obtain approval from the affiliated institution's ethical review committee for case reports that do not include comparative examination or statistical analysis. If the data is used for comparative examination or statistical analysis, the study should be considered an “observational study,” not “case reports,” and approval from the affiliated institution's ethical review committee is necessary.

    *Comparative examination generally means;

    • - A method that divides research participants into two or more groups for comparing differences between groups and performs statistical tests.
    • - A method that compares longitudinal data (e.g., before treatment vs. after treatment) of a research population and performs statistical tests.

  5. Guidelines for abstract contents
    • Abstract(s) must not have been presented at annual meetings including other societies at the time of submission.
    • Submitted abstracts will be peer-reviewed, so please avoid any mention of your affiliation in the title or body of your abstract.
    • When referring to drugs by name, please be certain to use the generic name.
    • It is mandatory to report the actual number of cases and/or laboratory animals/test specimens at the time of the experiment.
    • In principle, the abstracts should not report on single cases. However, upon review, such a presentation may be accepted if the case has been substantively examined from a symptomological and scientific perspective.
    • If the content infringes upon patients' personal information, informed consent must be obtained from the patient or their representative and the presentation must carefully avoid identifying any individuals. We prohibit presentations that include information, such as hospitalization dates, that could be used to identify individuals.
    • If the first author is not a native English speaker, abstracts should be proofread by a native English speaker before submission. Please note that if the English text is incomplete, it may be rejected by the peer review process.
    • The use of generative AI is prohibited for generating content in abstracts. However, it is permissible to use it for proofreading and editing the language of already written abstracts.
    • The Committee of Reviewers will review all the submitted abstracts, and the decision on abstract acceptance will be made by the Program Committee. Please note that a submitted abstract could be rejected depends on reviewing result.
    • If the first author is not a native English speaker, abstracts should be proofread by a native English speaker before submission. Please note that if the English text is incomplete, it may be rejected by the peer review process.
    • NEW The use of generative AI is prohibited for generating content in abstracts. However, it is permissible to use it for proofreading and editing the language of already written abstracts.
  6. Others
    • No matter what the reason, revisions to abstracts after submission deadline will not be accepted. The office will not request revisions for accepted abstracts. Submitted abstracts will appear as accepted in Clinical Neurology (vol. 65, issue Supplement). Revisions to abstracts after the annual meeting will not be accepted, so please prepare your abstracts with care.
    • The registration ID number and password are automatically generated, and sent to the first author by E-mail. You can view/edit/delete abstract at any time until the final deadline.
  7. Best presentation awards
    The JSN reviewers will give the best presentation awards to the best presenters (oral and poster) in nominees. The awards ceremony will be held in the Get Together on May 21 (Wednesday).

Disclosures of conflicts of interest

To promote appropriate forms of collaborative clinical research between industry and academia and ensure neutrality and transparency in presentations on clinical research findings based on sound science and ethics, all presenters are expected to disclose any "conflicts of interest" (COI).

When submitting proposals, please select "yes" or "no" in the field for "Do you have any conflicts of interest?" on the screen. If "yes," then please download and fill out the COI application form and send it to The Japanese Society of Neurology Secretariat office (jsn-abs@gol.com) as an e-mail attachment no later than December 6 (Friday), 2024. Technical questions regarding conflicts of interest should be directed to the society office as well.

Notification of Acceptance

Once the program is finalized, the acceptance/non-acceptance of abstracts will be announced on this website around mid-February. Please make a note of the "Abstract Entry Number (seven-digit number) " which will be shown in the E-mail sent immediately upon completion of your abstract submission. With the Abstract Entry Number, you will be able to find information such as presentation schedule, format and location on this webpage.
The decision on abstract acceptance is entirely up to the Program Committee.
No matter what the reason, request for change of your presentation schedule will not be accepted.

Online pre-registration by March 17 is required of all presenting authors (first authors.) Please understand that the abstracts of unregistered presenting authors on March 17 (Monday) will be withdrawn. Registration Categories for the first authors should be [Doctor / Researcher] or [JSN Overseas Membership].

Information for Speakers

Oral presentations
  • PC projectors are available for use.
  • Video projectors are not available, but video can be projected from PCs.
  • Presentation data must be provided on media (USB flash memory or CD-R). In the case of video, please bring your own PC.
  • Presentations should adhere to ethical rules of research as well as rules for protecting personal information.
  • Whether or not a presenter has any conflicts of interest, they must include a conflict-of-interest disclosure slide in their presentation. Please use "Form 4-D" or "Form 4-E."
  • Please do not use the company logos or product logos for the presentation slides.
Poster presentations
  • The anticipated size of poster panels is 210 cm tall × 90 cm wide. The Congress Secretariat will prepare the panel with only the presentation number at the top. Presenters are responsible for writing the presentation title, presenter name(s), and affiliation(s) horizontally within a 20 cm by 70 cm space.
  • In large, easy-to-understand language, the posters should present the Main Points as well as the Purpose, Methods, Results, and Discussion, all in that order. Text should be written in a large font that can be read from a distance of two to three meters, while diagrams should be at least 20 cm on a side and include a title and brief explanation.
  • The panels cannot be written or drawn on directly, nor can items be glued to them.
  • Pins to attach posters to the panels will be provided at the conference.
  • The schedule, etc. for poster presentations will be announced after notifications of abstract acceptance have been made.
  • Presentations should adhere to ethical rules of research as well as rules for protecting personal information.
  • Whether or not a presenter has any conflicts of interest, they must include a conflict-of-interest disclosure statement in their presentation. Please use "Form 4-F."

Travel Grant

The Japanese Society of Neurology encourages neurologists in other countries to submit abstracts on clinical studies and basic research in the oral and poster presentation. If Travel grant is approved, part of travel expenses (excluding accommodation expenses) will be covered by the Society. Please confirm the instructions before you apply for travel grant.

Abstract Submission (View / Edit / Delete)

Abstract Submission

※日本神経学会の会員(外国人会員以外)はここからではなく、必ず日本語サイトから登録してください。ここから登録されますと、「非会員海外演題」として認識されますのでご注意ください。
JSN members(excluding JSN overseas member)must submit abstracts from the Japanese page, not from here.

How to contact us

For inquiries regarding abstract submissions (free papers)

The Japanese Society of Neurology Secretariat

Ichimaru Bldg., 2-31-21 Yushima, Bunkyo-ku, Tokyo 113-0034
E-mail:jsn-abs@gol.com